Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03266588 · ClinicalTrials.gov registry record · Phase 2
Open Label Safety Study in Acute Treatment of Migraine
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 3,019
- Enrollment target
NCT03266588: Completed Phase 2 study, sponsored by Pfizer.
NCT03266588 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 3,019 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (2170% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03266588, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3,019 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate safety and tolerability of BHV-3000 (rimegepant).
Primary Outcome
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition on-treatment in a patient or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. An SAE was defined as any event that met any of the following criteria: death; life-threatening; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disabil
Interventions
- DRUG Rimegepant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,019 participants |
| Start Date | 2017-08-30 |
| Est. Completion | 2019-07-15 |
| Phase | Phase 2 |
What the finished NCT03266588 record still lists
NCT03266588 is an interventional study that assigns participants to a tested intervention. Its 3,019 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (2170% higher).
The record links to 0 conditions, and to 1 intervention - of which Rimegepant is the first listed.
NCT03266588 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03266588 about?
NCT03266588 is a clinical study titled "Open Label Safety Study in Acute Treatment of Migraine". The purpose of this study is to evaluate safety and tolerability of BHV-3000 (rimegepant).
What is the current status of trial NCT03266588?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3,019 participants. The study started on 2017-08-30. Estimated completion is 2019-07-15.
What interventions are being tested in trial NCT03266588?
The interventions under investigation include: Rimegepant (DRUG).
Who is sponsoring clinical trial NCT03266588?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03266588's enrollment target sits among peer trials
3,019 6th of 2000 higher than 1,995 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI